Romosozumab
Romosozumab Basic information
- Product Name:
- Romosozumab
- Synonyms:
-
- Romosozumab
- Research Grade Romosozumab(DHJ48701)
- AMG 785
- AMG785
- AMG-785
- CDP 7851
- CDP7851
- CDP-7851
- CAS:
- 909395-70-6
- MW:
- 0
- Mol File:
- Mol File
Romosozumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Romosozumab Usage And Synthesis
Uses
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2].
in vivo
Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys[1]. Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass, architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy[2].
| Animal Model: | Male cynomolgus monkeys[1] |
| Dosage: | 30 mg/kg |
| Administration: | Subcutaneous injection; 30 mg/kg twice a week for 10 weeks |
| Result: | Increased bone formation and plate-like trabecular morphology, and improved mechanical performance. |
References
[1] Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. DOI:10.1007/s40266-020-00793-8
[2] Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. DOI:10.1002/jbmr.3036
RomosozumabSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 18081075745
- chemflowtech@sina.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 400-1647117 13681763483
- product02@bidepharm.com